Cost-Effectiveness of Recombinant Human Erythropoietin for Reducing Red Blood Cells Transfusions in Critically Ill Patients

rHuEPO appears to be cost-effective for reducing RBC transfusions in heterogeneous ICU populations, assuming RBC transfusions increase the risk of nosocomial bacterial infections.